Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 37-5 - September 15, 2023
Editors: Bradley A. Mcgregor, Toni K. Choueiri
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 3 8 9 9 - 0
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 3 9 0 0 - 3

In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top… Read more

Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top experts in the field cover key topics such as VHL and HIF at the center of renal cell cancer biology; immunobiology and metabolic pathways of renal cell cancer; hereditary renal cell cancer syndromes; the role of the pathologist in renal cell cancer; novel imaging in renal cell cancer; and more.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Kidney cancer
von Hippel-Lindau disease
von Hippel-Lindau and sporadic clear cell renal cell carcinoma
Cooperating mutations
The von Hippel-Lindau tumor suppressor protein
The hypoxia-inducible factor transcription factor
HIF1α and cancer
HIF2α and clear cell renal cell carcinoma
Clear cell renal cell carcinoma therapeutics based on HIF2α biology
HIF2α inhibitors and cancer
Clinics care points
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Key points
Introduction
Immunobiology of renal cell carcinoma
Metabolic dysregulation in renal cell carcinoma
Summary
Clinics care points
Disclosure
Hereditary Renal Cell Carcinoma Syndromes
Key points
Introduction
Criteria for genetic evaluation of patients with renal cell carcinoma
Established renal cell carcinoma hereditary syndromes and clinical presentation
Screening guidelines
Summary
Funding
Clinics care points
The Role of the Pathologist in Renal Cell Carcinoma Management
Key points
Introduction
Classification of renal cell tumors: recent updates
Staging, grading, and other prognostic factors reported by pathologists
The role of pathologists in the development of personalized medicine strategies for renal cell carcinoma
Summary
Clinics care points
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Key points
Introduction
Summary
Clinics care points
Conflicts of interest
Surgical Management of Localized Disease and Small Renal Masses
Key points
Introduction
Preoperative evaluation and risk stratification
Nonsurgical management options
Surgical management
Summary
Clinics care points
Financial Disclosures/Conflicts of interest
Role of Surgery in Metastatic Renal Cell Carcinoma
Key points
Cytoreductive nephrectomy and cytokine therapies
Surgery and the evolving landscape of systemic therapies
Contemporary role of surgery for metastatic renal cell carcinoma
Summary
Clinics care points
Funding
Disclosure
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Key points
Introduction and rationale
Adjuvant Therapy
Adjuvant trials with immune checkpoint inhibitor
Adjuvant treatment with PD-1 inhibition
Discussion and recommendations
Clinics care points
Financial support and sponsorship
Disclosure
Role of Radiation in Treatment of Renal Cell Carcinoma
Key points
Background and historical context of radiotherapy for renal cell carcinoma
Radiotherapy for early stage renal cell carcinoma
Radiotherapy for metastatic renal cell carcinoma
Clinics care points
Prognostic Models in Metastatic Renal Cell Carcinoma
Key points
Introduction
Discussion
Summary
Clinics care points
Disclosure
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Key points
Introduction
Programmed cell death ligand 1 (PD-L1) expression
Genomic biomarkers
Transcriptomic profiling
Single-cell profiling
Gut microbiome
Summary
Clinics care points
Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
Key points
Introduction
Discussion
Summary
Clinics care points
Disclosure
First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Key points
Introduction and background
Historical trials
Front line systemic therapy
Discussion
Future directions
Summary
Clinics care points
Disclosure
Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Key points
Introduction
Rationale for treatment
Tyrosine kinase inhibitors
Immunotherapy
Novel therapies and combinations
Summary
Funding
Disclosures
Renal Cell Carcinoma of Variant Histology: Biology and Therapies
Key points
Introduction
Systemic therapies for variant histology renal cell carcinoma
Management of papillary renal cell carcinoma
Management of chromophobe renal cell carcinoma
Management of microphthalmia transcription factor renal cell carcinomas
Management of fumarate hydratase-deficient renal cell carcinoma
Management of renal medullary carcinoma
Management of collecting duct carcinoma
Management of unclassified renal cell carcinoma
Sarcomatoid or/and rhabdoid dedifferentiation
Adjuvant therapy considerations
Summary
Clinics care points
Disclosures
Toxicity Management of Systemic Kidney Cancer Therapies
Key points
Background on metastatic renal cell carcinoma and relevance of topic
Small molecule inhibitors of vascular endothelial growth factor receptors and mammalian target of rapamycin
Immune checkpoint inhibitors
Immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor combination therapies
Hypoxia-inducible factor-2alpha inhibitors
Concluding remarks
Clinics care points
Disclosure
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
Key points
Introduction
Current studies
Summary
Clinics care points
Disclosure
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Key points
Introduction
Hypoxia-inducible factor 2α inhibition
Cyclin-dependent kinase 4/6 inhibition
Targeting metabolic dysregulation
Novel receptor tyrosine kinase (RTK) inhibitors
Histone deacetylase pathway inhibition
Antibody-drug conjugates
Summary
Disclosure statement
Supplementary data
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
Key points
Introduction
Immune checkpoints
Myeloid receptors
Cytokine therapy
Role of the microbiome
Immuno-metabolic pathways
Adoptive T-cell therapy
Vaccines
Summary
Clinics care points

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Bradley A. Mcgregor

Toni K. Choueiri